Amalgamated Financial’s Neurocrine Biosciences NBIX Stock Holding History

Amalgamated Financial’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$6.63M	Buy	+70,662	New	+$5.99M	0.05%	327

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Amalgamated Financial's NBIX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Neurocrine Biosciences (NBIX) in Q1 2022: 70,662 shares worth $6.63M. The stake represents 0.05% of the portfolio and ranks #327 among its holdings.

427 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

Amalgamated Financial held 70,662 shares of Neurocrine Biosciences worth $6.63M as of Q1 2022.
Neurocrine Biosciences was a new Amalgamated Financial position in Q1 2022.
Neurocrine Biosciences made up 0.05% of Amalgamated Financial's portfolio in Q1 2022, its #327 holding.
427 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.